Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ocaña A[au]:

Search results

Items: 1 to 50 of 193

1.

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.

Serrano-Oviedo L, Nuncia-Cantarero M, Morcillo-Garcia S, Nieto-Jimenez C, Burgos M, Corrales-Sanchez V, Perez-Peña J, Győrffy B, Ocaña A, Galán-Moya EM.

Cell Oncol (Dordr). 2020 Mar 12. doi: 10.1007/s13402-020-00497-6. [Epub ahead of print]

PMID:
32166583
2.

Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis.

Desnoyers A, González C, Pérez-Segura P, Pandiella A, Amir E, Ocaña A.

Mol Diagn Ther. 2020 Apr;24(2):143-151. doi: 10.1007/s40291-020-00450-1. Review.

PMID:
32100239
3.

Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.

García-Alonso S, Ocaña A, Pandiella A.

Trends Cancer. 2020 Feb;6(2):130-146. doi: 10.1016/j.trecan.2019.12.010. Epub 2020 Jan 21. Review.

PMID:
32061303
4.

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.

Corrales-Sánchez V, Noblejas-López MDM, Nieto-Jiménez C, Pérez-Peña J, Montero JC, Burgos M, Galán-Moya EM, Pandiella A, Ocaña A.

J Cell Mol Med. 2020 Mar;24(5):3117-3127. doi: 10.1111/jcmm.14980. Epub 2020 Feb 7.

5.

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.

Ocaña A, Amir E, Pandiella A.

Breast Cancer Res. 2020 Jan 31;22(1):15. doi: 10.1186/s13058-020-1252-7. Review.

6.

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors.

Alcaraz-Sanabria A, Baliu-Piqué M, Saiz-Ladera C, Rojas K, Manzano A, Marquina G, Casado A, Cimas FJ, Pérez-Segura P, Pandiella A, Gyorffy B, Ocana A.

Front Oncol. 2020 Jan 10;9:1486. doi: 10.3389/fonc.2019.01486. eCollection 2019.

7.

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.

Pérez-Pena J, Tibor Fekete J, Páez R, Baliu-Piqué M, García-Saenz JÁ, García-Barberán V, Manzano A, Pérez-Segura P, Esparis-Ogando A, Pandiella A, Gyorffy B, Ocana A.

Front Immunol. 2019 Dec 18;10:2802. doi: 10.3389/fimmu.2019.02802. eCollection 2019.

8.

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer.

Niza E, Noblejas-López MDM, Bravo I, Nieto-Jiménez C, Castro-Osma JA, Canales-Vázquez J, Lara-Sanchez A, Galán Moya EM, Burgos M, Ocaña A, Alonso-Moreno C.

Nanomaterials (Basel). 2019 Dec 16;9(12). pii: E1793. doi: 10.3390/nano9121793.

9.

Functioning of autobiographical memory specificity and self-defining memories in people with cancer diagnosis.

Nieto M, Navarro-Bravo B, Moreno B, Ocana A, Serrano JP, Boix Gras C, Ricarte J, Fernández-Aguilar L, Ros L, Latorre JM.

PeerJ. 2019 Dec 19;7:e8126. doi: 10.7717/peerj.8126. eCollection 2019.

10.

Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.

Ríos-Luci C, Díaz-Rodríguez E, Gandullo-Sánchez L, Díaz-Gil L, Ocaña A, Pandiella A.

Cancer Lett. 2020 Feb 1;470:161-169. doi: 10.1016/j.canlet.2019.11.026. Epub 2019 Nov 22.

PMID:
31765734
11.

Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.

Saleh RR, Peinado P, Fuentes-Antrás J, Pérez-Segura P, Pandiella A, Amir E, Ocaña A.

Front Oncol. 2019 Oct 15;9:1040. doi: 10.3389/fonc.2019.01040. eCollection 2019.

12.

Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.

Noblejas-López MDM, Nieto-Jiménez C, Morcillo García S, Pérez-Peña J, Nuncia-Cantarero M, Andrés-Pretel F, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocana A.

Oncoimmunology. 2019 Jul 3;8(10):e1629780. doi: 10.1080/2162402X.2019.1629780. eCollection 2019.

PMID:
31646075
13.

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.

Wali VB, Patwardhan GA, Pelekanou V, Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L.

Sci Rep. 2019 Oct 17;9(1):14934. doi: 10.1038/s41598-019-51453-w.

14.

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.

Noblejas-López MDM, Nieto-Jimenez C, Burgos M, Gómez-Juárez M, Montero JC, Esparís-Ogando A, Pandiella A, Galán-Moya EM, Ocaña A.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383. doi: 10.1186/s13046-019-1387-5.

15.

Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy.

Niza E, Nieto-Jiménez C, Noblejas-López MDM, Bravo I, Castro-Osma JA, Cruz-Martínez F, Buchaca MMS, Posadas I, Canales-Vázquez J, Lara-Sanchez A, Hermida-Merino D, Solano E, Ocaña A, Alonso-Moreno C.

Nanomaterials (Basel). 2019 Aug 27;9(9). pii: E1208. doi: 10.3390/nano9091208.

16.

Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models.

Corrales Sánchez V, Nieto-Jiménez C, Castro-Osma JA, de Andrés F, Pacheco-Liñán PJ, Bravo I, Rodríguez Fariñas N, Niza E, Domínguez-Jurado E, Lara-Sánchez A, Ríos Á, Gómez Juárez M, Montero JC, Pandiella A, Shafir A, Alonso-Moreno C, Ocaña A.

ACS Omega. 2019 Aug 1;4(8):13005-13014. doi: 10.1021/acsomega.9b00296. eCollection 2019 Aug 20.

17.

Medical Oncology Workload in Europe: One Continent, Several Worlds.

Seruga B, Sullivan R, Fundytus A, Hopman WM, Ocana A, Joffe J, Bodoky G, Le Tourneau C, Vanderpuye V, Lopes G, Hammad N, Sengar M, Brundage MD, Booth CM.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e19-e26. doi: 10.1016/j.clon.2019.06.017. Epub 2019 Jul 16.

PMID:
31324474
18.

Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.

Eur Urol Oncol. 2019 Jul;2(4):448-455. doi: 10.1016/j.euo.2018.10.003. Epub 2018 Nov 5. Review.

PMID:
31277782
19.

Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

Saleh RR, Antrás JF, Peinado P, Pérez-Segura P, Pandiella A, Amir E, Ocaña A.

Cancer Treat Rev. 2019 Jul;77:11-19. doi: 10.1016/j.ctrv.2019.05.006. Epub 2019 May 29.

PMID:
31174180
20.

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Perez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A.

PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.

21.

Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population.

Fernández-Mateos J, Seijas-Tamayo R, Adansa Klain JC, Pastor Borgoñón M, Pérez-Ruiz E, Mesía R, Del Barco E, Salvador Coloma C, Rueda Dominguez A, Caballero Daroqui J, Fernández Ruiz E, Ocana A, González-Sarmiento R, Cruz-Hernández JJ.

Cancers (Basel). 2019 Apr 7;11(4). pii: E493. doi: 10.3390/cancers11040493.

22.

Mapping Bromodomains in breast cancer and association with clinical outcome.

Pérez-Pena J, Páez R, Nieto-Jiménez C, Sánchez VC, Galan-Moya EM, Pandiella A, Győrffy B, Ocana A.

Sci Rep. 2019 Apr 5;9(1):5734. doi: 10.1038/s41598-019-41934-3.

23.

TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.

Díaz-Rodríguez E, Pérez-Peña J, Ríos-Luci C, Arribas J, Ocaña A, Pandiella A.

Cancer Lett. 2019 Jul 1;453:34-44. doi: 10.1016/j.canlet.2019.03.042. Epub 2019 Mar 27.

PMID:
30928382
24.

Gas-phase reactivity of CH3OH toward OH at interstellar temperatures (11.7-177.5 K): experimental and theoretical study.

Ocaña AJ, Blázquez S, Potapov A, Ballesteros B, Canosa A, Antiñolo M, Vereecken L, Albaladejo J, Jiménez E.

Phys Chem Chem Phys. 2019 Mar 27;21(13):6942-6957. doi: 10.1039/c9cp00439d.

25.

Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.

Shepshelovich D, Tibau A, Goldvaser H, Ocana A, Seruga B, Amir E.

Mayo Clin Proc. 2019 Jan;94(1):74-83. doi: 10.1016/j.mayocp.2018.07.027.

PMID:
30611457
26.

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Antolín S, Atienza M, Montaño Á, Ribelles N, Urruticoechea A, Falcón A, Pernas S, Orlando J, Montero JC, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A, Ruiz-Borrego M.

Breast Cancer Res Treat. 2019 Apr;174(3):693-701. doi: 10.1007/s10549-018-05100-z. Epub 2019 Jan 3.

PMID:
30607629
27.

Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual.

Shepshelovich D, Tibau A, Molto C, Goldvaser H, Ocana A, Šeruga B, Amir E.

JAMA Oncol. 2019 Jan 1;5(1):107-109. doi: 10.1001/jamaoncol.2018.5877. No abstract available.

28.

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.

Noblejas-López MDM, Morcillo-García S, Nieto-Jiménez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM, Pandiella A, Ocaña A.

PLoS One. 2018 Nov 28;13(11):e0207776. doi: 10.1371/journal.pone.0207776. eCollection 2018.

29.

Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis.

Goldvaser H, Ribnikar D, Majeed H, Ocaña A, Amir E.

Cancer Treat Rev. 2018 Dec;71:68-75. doi: 10.1016/j.ctrv.2018.10.010. Epub 2018 Oct 17. Review.

PMID:
30366201
30.

Refining Early Antitumoral Drug Development.

Ocaña A, García-Alonso S, Amir E, Pandiella A.

Trends Pharmacol Sci. 2018 Nov;39(11):922-925. doi: 10.1016/j.tips.2018.09.003. Epub 2018 Sep 29. Review.

PMID:
30279003
31.

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A.

Breast Cancer Res Treat. 2018 Dec;172(3):725-732. doi: 10.1007/s10549-018-4965-x. Epub 2018 Sep 11.

PMID:
30206781
32.

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results.

Ocaña A, Amir E, Pandiella A.

Oncotarget. 2018 Aug 7;9(61):31915-31919. doi: 10.18632/oncotarget.25739. eCollection 2018 Aug 7. Review.

33.

Is the gas-phase OH+H2CO reaction a source of HCO in interstellar cold dark clouds? A kinetic, dynamic and modelling study.

Ocaña AJ, Jiménez E, Ballesteros B, Canosa A, Antiñolo M, Albaladejo J, Agúndez M, Cernicharo J, Zanchet A, Del Mazo P, Roncero O, Aguado A.

Astrophys J. 2017 Nov 20;850(1). pii: 28. doi: 10.3847/1538-4357/aa93d9. Epub 2017 Nov 14.

34.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.

Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A; GEICAM 9906 Study Investigators.

Clin Transl Oncol. 2018 Dec;20(12):1548-1556. doi: 10.1007/s12094-018-1885-5. Epub 2018 May 15.

PMID:
29766456
35.

Resistance to Antibody-Drug Conjugates.

García-Alonso S, Ocaña A, Pandiella A.

Cancer Res. 2018 May 1;78(9):2159-2165. doi: 10.1158/0008-5472.CAN-17-3671. Epub 2018 Apr 13. Review.

36.

Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.

Shepshelovich D, Tibau A, Goldvaser H, Molto C, Ocana A, Seruga B, Amir E.

J Clin Oncol. 2018 Jun 20;36(18):1798-1804. doi: 10.1200/JCO.2017.77.5593. Epub 2018 Apr 11.

PMID:
29641296
37.

Selection of tawny owl (Strix aluco) flight feather shaft for biomonitoring As, Cd and Pb pollution.

Seoane RG, Río ZV, Ocaña AC, Escribano JÁF, Viñas JRA.

Environ Sci Pollut Res Int. 2018 May;25(14):14271-14276. doi: 10.1007/s11356-018-1477-5. Epub 2018 Apr 7.

PMID:
29627961
38.

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer.

Tibau A, Anguera G, Andrés-Pretel F, Templeton AJ, Seruga B, Barnadas A, Amir E, Ocana A.

Oncotarget. 2018 Feb 28;9(19):15061-15067. doi: 10.18632/oncotarget.24589. eCollection 2018 Mar 13.

39.

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A.

Cancer Med. 2018 May;7(5):1896-1907. doi: 10.1002/cam4.1406. Epub 2018 Mar 25.

40.

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.

Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, Sánchez-Aragó M, Carrasco E, Caballero R, Amir E, Martin M.

Eur J Cancer. 2018 May;94:199-205. doi: 10.1016/j.ejca.2018.02.018. Epub 2018 Mar 21.

PMID:
29573665
41.

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.

Goldvaser H, Majeed H, Ribnikar D, Šeruga B, Ocaña A, Cescon DW, Amir E.

Breast Cancer Res Treat. 2018 Jun;169(3):413-425. doi: 10.1007/s10549-018-4710-5. Epub 2018 Feb 8. Review.

PMID:
29423899
42.

Gas phase kinetics of the OH + CH3CH2OH reaction at temperatures of the interstellar medium (T = 21-107 K).

Ocaña AJ, Blázquez S, Ballesteros B, Canosa A, Antiñolo M, Albaladejo J, Jiménez E.

Phys Chem Chem Phys. 2018 Feb 21;20(8):5865-5873. doi: 10.1039/c7cp07868d.

43.

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Santpere G, Alcaráz-Sanabria A, Corrales-Sánchez V, Pandiella A, Győrffy B, Ocaña A.

Oncotarget. 2017 Dec 8;9(1):453-463. doi: 10.18632/oncotarget.23065. eCollection 2018 Jan 2.

44.

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis.

Barua R, Templeton AJ, Seruga B, Ocana A, Amir E, Ethier JL.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):215-224. doi: 10.1016/j.clon.2018.01.003. Epub 2018 Feb 12.

PMID:
29395413
45.

Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.

Nuncia-Cantarero M, Martinez-Canales S, Andrés-Pretel F, Santpere G, Ocaña A, Galan-Moya EM.

Breast Cancer Res Treat. 2018 Apr;168(3):613-623. doi: 10.1007/s10549-017-4652-3. Epub 2018 Jan 12.

46.

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, Booth CM, Amir E.

J Natl Cancer Inst. 2018 May 1;110(5):486-492. doi: 10.1093/jnci/djx232.

PMID:
29244173
47.

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Perez-Peña J, Corrales-Sánchez V, Amir E, Pandiella A, Ocana A.

Sci Rep. 2017 Dec 13;7(1):17530. doi: 10.1038/s41598-017-17836-7.

48.

Reporting of Randomized Trials in Common Cancers in the Lay Media.

Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E.

Oncology. 2018;94(2):65-71. doi: 10.1159/000484630. Epub 2017 Nov 18.

PMID:
29151109
49.

Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.

Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.

Cancer Treat Rev. 2018 Jan;62:1-8. doi: 10.1016/j.ctrv.2017.10.008. Epub 2017 Oct 31. Review.

PMID:
29126017
50.

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A.

Oncotarget. 2017 Apr 14;8(42):73144-73153. doi: 10.18632/oncotarget.17113. eCollection 2017 Sep 22.

Supplemental Content

Support Center